DuPont Animal Nutrition to partner with Proteon Pharmaceuticals

bacteriophage

DuPont Animal Nutrition, a business unit of DuPont Nutrition & Biosciences (DuPont), recently announced a partnership with Proteon Pharmaceuticals, a Polish biotechnology company and leader in bacteriophage technology for livestock farming, to bring emerging bacteriophage technology to poultry producers in selected countries. This strategic partnership will strengthen DuPont’s gut health solutions for poultry and expand Proteon’s distribution capabilities, as well as helping to further mitigate antimicrobial resistance (AMR) in farm animals.

The threat of antimicrobial resistance has sparked recent investment into bacteriophage technologies. Modern analyticical techniques and -omics technologies have enabled the screening and identification of bacteriophage candidates for a specific bacterial challenge, with significant feed and food safety implications.

DuPont invited Proteon Pharmaceuticals to partner for their compatible work culture, solid scientific approach, and leading position among their peers in bringing phage technology to market.

“Proteon Pharmaceuticals is a pioneer in bacteriophage technology used in animal farming. They have been developing this technology for more than 10 years. It has been tested in Europe and Asia and proven in terms of efficacy and stability. This technology fits with our nutribiotic approach. We are pleased to add it to our range of solutions for poultry producers.”

Aart Mateboer, business leader at DuPont Animal Nutrition.

Poultry farmers in selected markets are already benefiting from using Proteon’s technology to ensure biosecurity via the waterline and to improve production efficiency.

“We strongly believe that our technology might be considered as the future of animal health and nutrition and will help to reduce antibiotic use and antimicrobial resistance. We are excited to take this next step with DuPont to bring the benefits of bacteriophage technology as a feed additive to poultry producers globally.”

Jarosław Dastych, chief executive officer of Proteon Pharmaceuticals.

For more information on this strategic partnership, visit the DuPont Newsroom.

Leave a Reply

Your email address will not be published. Required fields are marked *